Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744391 · ClinicalTrials.gov registry record · Phase 4
A Study of L-DOPA for Depression and Slowing in Older Adults
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT02744391 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 47 participants.
The verdict
NCT02744391, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response. Our group and others have shown that decreased thinking speed is the central cause of functional problems in patients with LLD. Similarly, decreased walking speed is associated with depression and carries additional risk for falls, hospitalization, and death. Available evidence suggests that declining functionality in the brain's dopamine system contributes to age-related cognitive and motor slowing. The central hypothesis of this R61/R33 Phased Innovation Award is that by enhancing dopamine functioning in the brain and improving cognitive and motor slowing, administration of carbidopa/levodopa (L-DOPA) will improve depressive symptoms in older adults.
Interventions
- DRUG Levodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2016-08-24 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744391
The ClinicalTrials.gov registry entry for NCT02744391 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levodopa is the first listed.
NCT02744391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02744391 about?
NCT02744391 is a clinical study titled "A Study of L-DOPA for Depression and Slowing in Older Adults". Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response. Our group and others have shown that decreased thinking speed is the central cause of functional probl...
What is the current status of trial NCT02744391?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2016-08-24. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT02744391?
The interventions under investigation include: Levodopa (DRUG).
Who is sponsoring clinical trial NCT02744391?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.